MX2017009452A - Agentes de imagenologia para tomografia de emision de positrones (pet). - Google Patents

Agentes de imagenologia para tomografia de emision de positrones (pet).

Info

Publication number
MX2017009452A
MX2017009452A MX2017009452A MX2017009452A MX2017009452A MX 2017009452 A MX2017009452 A MX 2017009452A MX 2017009452 A MX2017009452 A MX 2017009452A MX 2017009452 A MX2017009452 A MX 2017009452A MX 2017009452 A MX2017009452 A MX 2017009452A
Authority
MX
Mexico
Prior art keywords
imaging agents
pet imaging
formula
preparation
novel
Prior art date
Application number
MX2017009452A
Other languages
English (en)
Spanish (es)
Inventor
Oberhauser Berndt
Briard Emmanuelle
Auberson Yves
Legrand Darren
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2017009452A publication Critical patent/MX2017009452A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00Diagnosis using ultrasonic, sonic or infrasonic waves
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • Engineering & Computer Science (AREA)
  • Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nuclear Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MX2017009452A 2015-01-20 2016-01-20 Agentes de imagenologia para tomografia de emision de positrones (pet). MX2017009452A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562105336P 2015-01-20 2015-01-20
PCT/IB2016/050276 WO2016116875A1 (en) 2015-01-20 2016-01-20 Pet imaging agents

Publications (1)

Publication Number Publication Date
MX2017009452A true MX2017009452A (es) 2017-11-08

Family

ID=55300733

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009452A MX2017009452A (es) 2015-01-20 2016-01-20 Agentes de imagenologia para tomografia de emision de positrones (pet).

Country Status (12)

Country Link
US (2) US10450298B2 (enExample)
EP (1) EP3247706B1 (enExample)
JP (2) JP6723264B2 (enExample)
KR (1) KR20170103960A (enExample)
CN (1) CN107406419B (enExample)
AU (1) AU2016209906A1 (enExample)
BR (1) BR112017015455A2 (enExample)
CA (1) CA2974311A1 (enExample)
EA (1) EA201791643A1 (enExample)
ES (1) ES2828715T3 (enExample)
MX (1) MX2017009452A (enExample)
WO (1) WO2016116875A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2974311A1 (en) 2015-01-20 2016-07-28 Novartis Ag Pet imaging agents
TWI809597B (zh) * 2020-12-16 2023-07-21 美商美國禮來大藥廠 預靶向造影劑

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0224917D0 (en) * 2002-10-25 2002-12-04 Novartis Ag Organic compounds
WO2005043300A2 (en) 2003-10-20 2005-05-12 Empirix, Inc. Computer language interpretation and optimization for server testing
BRPI0510512A (pt) 2004-04-28 2007-10-30 Icos Corp derivados de arilfenilamino, arilfenilamida e sulfeto de arilfeniléter
WO2005121094A1 (en) 2004-06-09 2005-12-22 Pfizer Limited Piperazine and piperidine derivatives as anti-hiv-agents
CN101429161A (zh) * 2008-12-05 2009-05-13 常熟理工学院 Pet显像剂前体异喹啉甲酰胺衍生物的合成方法
JP5767205B2 (ja) * 2009-04-02 2015-08-19 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung オートタキシン阻害剤としての複素環式化合物
US8999974B2 (en) 2010-08-09 2015-04-07 Raqualia Pharma Inc. Acyl piperazine derivatives as TTX-S blockers
JP2013536200A (ja) * 2010-08-20 2013-09-19 アミラ ファーマシューティカルス,インコーポレーテッド オートタキシン阻害剤およびその使用
PT2861566T (pt) * 2012-06-13 2017-02-08 Hoffmann La Roche Novos diazaspirocicloalcanos e azaspirocicloalcanos
CN104968656B (zh) * 2012-12-19 2017-08-11 诺华股份有限公司 自分泌运动因子抑制剂
SG11201600241RA (en) 2013-07-18 2016-02-26 Novartis Ag Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
CA2974311A1 (en) 2015-01-20 2016-07-28 Novartis Ag Pet imaging agents

Also Published As

Publication number Publication date
CN107406419A (zh) 2017-11-28
US20200017474A1 (en) 2020-01-16
US20180273509A1 (en) 2018-09-27
EA201791643A1 (ru) 2017-11-30
EP3247706A1 (en) 2017-11-29
US10450298B2 (en) 2019-10-22
AU2016209906A1 (en) 2017-08-03
EP3247706B1 (en) 2020-07-08
KR20170103960A (ko) 2017-09-13
ES2828715T3 (es) 2021-05-27
CA2974311A1 (en) 2016-07-28
BR112017015455A2 (pt) 2018-01-23
JP6723264B2 (ja) 2020-07-15
US10865195B2 (en) 2020-12-15
CN107406419B (zh) 2020-09-11
CN107406419A8 (zh) 2018-01-12
JP2018511648A (ja) 2018-04-26
JP2020158532A (ja) 2020-10-01
WO2016116875A1 (en) 2016-07-28

Similar Documents

Publication Publication Date Title
MX2017006302A (es) Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
PH12017500941A1 (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
CA2990901C (en) SUBSTITUTED OXOPYRIDINE DERIVATIVES
MY192717A (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
EP3778605A3 (en) Lrrk2 inhibitors and methods of making and using the same
PH12016501898A1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
PH12015502216A1 (en) Compositions and methods for improving the health of aquatic animals
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
MX385332B (es) Moduladores de ror-gamma.
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
NZ758528A (en) Bicyclic heterocycle compounds and their uses in therapy
MX381383B (es) Compuestos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol sustituidos como agentes de direccionamiento al receptor de asialoglicoproteina (asgpr)
EA201691141A1 (ru) Соединения против ccr6
PH12017501077A1 (en) Compositions and methods for antibodies targeting bmp6
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
EA201691541A1 (ru) Новые анти-baff антитела
MX388170B (es) Polimorfos de selinexor
MY193728A (en) Muscarinic receptor agonists
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
EA201890572A1 (ru) Биофармацевтические композиции
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
MX2017003254A (es) 2-azabiciclos sustituidos y su uso como moduladores de receptores de orexina.
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
WO2016138538A3 (en) Therapeutic use of integrin-binding antibodies